- Home
- NKSH vs EYPT Comparison
NKSH vs EYPT Comparison
Compare NKSH & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NKSH | EYPT |
|---|---|---|
| Founded | 1891 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.1M | 273.3M |
| IPO Year | 1995 | 2005 |
Fundamental Metrics
Financial Performance| Metric | NKSH | EYPT |
|---|---|---|
| Price | $40.43 | $0.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $25.91 |
| AVG Volume (30 Days) | 22.6K | ★ 13.4M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.32% | N/A |
| EPS Growth | ★ 100.81 | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $8,176,000.00 | $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $967.16 |
| P/E Ratio | $28.96 | ★ N/A |
| Revenue Growth | ★ 9.39 | N/A |
| 52 Week Low | $27.00 | $0.39 |
| 52 Week High | $45.65 | $19.11 |
Technical Indicators
Market Signals| Indicator | NKSH | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 38.55 | 15.29 |
| Support Level | $34.71 | N/A |
| Resistance Level | $43.04 | $3.57 |
| Average True Range (ATR) | 1.39 | 0.16 |
| MACD | -0.09 | -0.19 |
| Stochastic Oscillator | 11.91 | 0.70 |
Price Performance
Historical ComparisonAbout NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural loans, commercial real estate, construction loans for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary. The company earns its revenue from interest and fees on loans, non-interest income, and investments.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.